[go: up one dir, main page]

MX2016006241A - Formas morficas de esteres de hexadeciloxipropil-fosfonato. - Google Patents

Formas morficas de esteres de hexadeciloxipropil-fosfonato.

Info

Publication number
MX2016006241A
MX2016006241A MX2016006241A MX2016006241A MX2016006241A MX 2016006241 A MX2016006241 A MX 2016006241A MX 2016006241 A MX2016006241 A MX 2016006241A MX 2016006241 A MX2016006241 A MX 2016006241A MX 2016006241 A MX2016006241 A MX 2016006241A
Authority
MX
Mexico
Prior art keywords
hexadecyloxypropyl
phosphonate esters
morphic forms
ester compounds
phosphonate ester
Prior art date
Application number
MX2016006241A
Other languages
English (en)
Other versions
MX362752B (es
Inventor
Wendell Ware Roy
Leigh Downey Aaron
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of MX2016006241A publication Critical patent/MX2016006241A/es
Publication of MX362752B publication Critical patent/MX362752B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

La descripción describe métodos de síntesis de compuestos de éster de fosfonato. Los métodos de acuerdo a la descripción permiten la preparación a gran escala de compuestos de éster de fosfonato que tienen alta pureza y estabilidad. También se describen formas mórficas de compuestos de éster de fosfonato.
MX2016006241A 2013-11-15 2014-10-10 Formas mórficas de ésteres de hexadeciloxipropil-fosfonato. MX362752B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904857P 2013-11-15 2013-11-15
PCT/US2014/060185 WO2015073148A1 (en) 2013-11-15 2014-10-10 Morphic forms of hexadecyloxypropyl-phosphonate esters

Publications (2)

Publication Number Publication Date
MX2016006241A true MX2016006241A (es) 2016-09-06
MX362752B MX362752B (es) 2019-02-07

Family

ID=52472937

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006241A MX362752B (es) 2013-11-15 2014-10-10 Formas mórficas de ésteres de hexadeciloxipropil-fosfonato.

Country Status (15)

Country Link
US (8) US8962829B1 (es)
EP (1) EP2999476B1 (es)
JP (3) JP6150949B2 (es)
KR (3) KR20170143009A (es)
CN (2) CN111777639A (es)
AU (3) AU2014349103B2 (es)
BR (1) BR112016010862B1 (es)
CA (1) CA2929593C (es)
DK (1) DK2999476T3 (es)
EA (1) EA031861B1 (es)
ES (1) ES2685819T3 (es)
IL (3) IL302520A (es)
MX (1) MX362752B (es)
UA (1) UA116825C2 (es)
WO (1) WO2015073148A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2809679C (en) * 2010-08-31 2018-03-20 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
TWI642677B (zh) 2013-03-15 2018-12-01 美國加利福尼亞大學董事會 非環狀核苷膦酸二酯
CN111777639A (zh) * 2013-11-15 2020-10-16 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
EA036391B1 (ru) 2014-09-15 2020-11-05 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Нуклеотидные аналоги
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
CN114569547A (zh) * 2016-06-28 2022-06-03 奇默里克斯公司 布林西多福韦的制剂
JP7465416B2 (ja) 2018-06-26 2024-04-11 ティーエスアールエル インコーポレイテッド 代謝安定性プロドラッグ
US20220135653A1 (en) * 2020-11-05 2022-05-05 Bravado Pharmaceuticals, LLC Intranasal Antiviral Therapy for Mucosal Protection Against Virus Infections
JP2025526212A (ja) 2022-07-21 2025-08-13 アンティバ バイオサイエンシズ インコーポレイテッド Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形
CN119462754B (zh) * 2024-09-30 2025-11-07 武汉大学中南医院 一种布林西多福韦化合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0574386B1 (en) * 1990-08-10 2000-06-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel process for the preparation of nucleotides
CA2347911A1 (en) * 1998-10-23 2000-05-04 Darwin Discovery Limited Single morphic forms of known peptide metalloproteinase inhibitors
DE60038038T2 (de) 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
US20020022659A1 (en) * 2000-07-19 2002-02-21 Harris Gregory D. Crystalline and salt forms of an HIV protease inhibitor
EP1667524A4 (en) * 2003-09-23 2009-01-14 Merck & Co Inc NEW CRYSTALLINE FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
WO2006014429A2 (en) * 2004-07-02 2006-02-09 University Of Southern California (La) Cidofovir peptide conjugates as prodrugs
US7612072B2 (en) * 2004-09-15 2009-11-03 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP1865967A4 (en) 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
ES2600792T3 (es) * 2006-05-03 2017-02-10 Chimerix, Inc. Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
ES2532502T3 (es) * 2006-07-12 2015-03-27 Mylan Laboratories Limited Proceso para la preparación de tenofovir
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
ES2609095T3 (es) * 2007-04-27 2017-04-18 Chimerix, Inc. Métodos de reducción de la nefrotoxicidad en sujetos a quienes se administra nucleósido
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101143879A (zh) * 2007-11-08 2008-03-19 上海交通大学 含硫无环核苷膦酸类似物及其制备方法
JP2011506374A (ja) * 2007-12-12 2011-03-03 ウルティモルフィクス・テクノロジーズ・ベー・フェー テノホビルジソプロキシルの固形物
US8614200B2 (en) * 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
JP2013501056A (ja) 2009-08-03 2013-01-10 キメリクス，インコーポレイテッド ウイルス感染およびウイルス誘発腫瘍を治療する組成物および方法
AU2010313273B2 (en) 2009-10-30 2015-04-02 Emergent Biodefense Operations Lansing Llc Methods of treating viral associated diseases
DK2534150T3 (en) * 2010-02-12 2017-06-12 Chimerix Inc METHODS OF TREATING VIRUS INFECTION
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2809679C (en) * 2010-08-31 2018-03-20 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
EP2770834A4 (en) * 2011-10-26 2015-11-25 Chimerix Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
WO2013163509A1 (en) * 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
CN104797259A (zh) * 2012-07-03 2015-07-22 奇默里克斯公司 治疗逆转录病毒感染的方法和相关剂量方案
CN111777639A (zh) * 2013-11-15 2020-10-16 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
CA2932423A1 (en) * 2013-12-05 2015-06-11 Chimerix, Inc. Branched chain acyclic nucleoside phosphonate esters and methods of synthesis and uses thereof
CN114569547A (zh) * 2016-06-28 2022-06-03 奇默里克斯公司 布林西多福韦的制剂

Also Published As

Publication number Publication date
JP6401820B2 (ja) 2018-10-10
JP2017200919A (ja) 2017-11-09
CN105899215A (zh) 2016-08-24
IL302520A (en) 2023-07-01
IL245576B (en) 2022-03-01
AU2017203315A1 (en) 2017-06-08
JP2016538326A (ja) 2016-12-08
BR112016010862A8 (pt) 2020-04-22
KR20170143009A (ko) 2017-12-28
US10112909B2 (en) 2018-10-30
IL245576A0 (en) 2016-06-30
CA2929593C (en) 2020-03-10
UA116825C2 (uk) 2018-05-10
US20240217938A1 (en) 2024-07-04
BR112016010862A2 (pt) 2017-08-08
MX362752B (es) 2019-02-07
US10487061B2 (en) 2019-11-26
EA201691006A1 (ru) 2017-02-28
BR112016010862B1 (pt) 2022-11-29
ES2685819T3 (es) 2018-10-11
JP6150949B2 (ja) 2017-06-21
KR20160078500A (ko) 2016-07-04
KR20170143010A (ko) 2017-12-28
US11066373B2 (en) 2021-07-20
AU2017202386A1 (en) 2017-04-27
EP2999476A4 (en) 2016-04-13
US20180086721A1 (en) 2018-03-29
US20220144782A1 (en) 2022-05-12
AU2014349103A1 (en) 2016-06-16
EP2999476A1 (en) 2016-03-30
US9862687B2 (en) 2018-01-09
US9371344B2 (en) 2016-06-21
KR101812433B1 (ko) 2017-12-26
JP2017200920A (ja) 2017-11-09
AU2014349103B2 (en) 2017-01-12
WO2015073148A1 (en) 2015-05-21
EA031861B1 (ru) 2019-03-29
CN111777639A (zh) 2020-10-16
CA2929593A1 (en) 2015-05-21
US20190016687A1 (en) 2019-01-17
EP2999476B1 (en) 2018-08-08
DK2999476T3 (en) 2018-09-03
US20200095208A1 (en) 2020-03-26
US20160264531A1 (en) 2016-09-15
US20150210724A1 (en) 2015-07-30
IL279291A (en) 2021-01-31
US8962829B1 (en) 2015-02-24
US11912667B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
MX2016006241A (es) Formas morficas de esteres de hexadeciloxipropil-fosfonato.
GB2518547B (en) Method for the preparation of high purity lignin
WO2014164533A8 (en) Methods of stereoselective synthesis of substituted nucleoside analogs
EP3047030A4 (en) A high yield route for the production of compounds from renewable sources
PL2693881T3 (pl) Podstawione analogi N-fenylopirymidyno-2-aminy jako inhibitory kinazy AXL
EP3077399A4 (en) Methods useful in the synthesis of halichondrin b analogs
SI2984490T1 (sl) Metode proizvodnje derivatov omega hidroksilirane maščobne kisline
EP3040407A4 (en) Method for producing high purity omega-3 fatty acid ethyl ester
IN2015DN02376A (es)
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
ZA201505457B (en) Process for the preparation of succinic acid ester
ZA201505352B (en) Process for the preparation of succinic acid ester
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
EP3048172A4 (en) Method for producing l-amino acid from seaweed-derived biomass
IN2013MU03070A (es)
EP2986147A4 (en) PROCESS FOR PREPARING A BREAD COMPOSITION
GB2528618B (en) Chromatographic process for the production of highly purified polyunsaturated fatty acids
ZA201603839B (en) Process for the production of synthesis gas
FR3003872B1 (fr) Procede de stabilisation des metabolites sensibles a l'oxydation produits par les microalgues du genre chlorella
MX361673B (es) Procedimiento para la preparación de intermediarios de ácido borónico.
IN2014DN07498A (es)
IN2013MU02748A (es)
GB2503103B8 (en) Process for the production of fatty acid esters
IN2013MU02612A (es)
HUP1200570A2 (en) Process for the incorporation of micro- and mesoelements and other compounds having positive effect on the yield into the soil

Legal Events

Date Code Title Description
FG Grant or registration